注射用重组人白细胞介素-2免疫辅助治疗复治肺结核的临床效果

Clinical effect of recombinant human interleukin-2 immunization for injection in adjuvant therapy for pulmonary tuberculosis

目的探讨与分析注射用重组人白细胞介素-2免疫辅助治疗复治肺结核的临床效果和不良反应。方法将64例复治肺结核患者随机分为对照组(n=32)和治疗组(n=32),对照组采用2H3R3Z3E3S3/6H3R3E3抗结核化疗方案治疗,而治疗组在此基础上采用联合应用注射用重组人白细胞介素-2皮下注射治疗,隔日1次,连续应用2个月。通过检查两组治疗前后的痰涂片镜检及X线胸片检查的结果等,来比较分析两组患者的临床治疗效果及不良反应。结果治疗组的痰菌阴转率明显高于对照组(29/22例),差异有统计学意义(P <0.05);治疗组的病灶显著吸收率(19/11例)、空洞的闭合率(15/7例)均优于对照组,差异有统计学意义(P <0.05);两组患者不良反应发生率比较,差异无统计学意义(P> 0.05)。结论注射用重组人白细胞介素-2免疫辅助治疗复治肺结核疗效显著,安全可靠,值得临床推广应用。

Objective To discuss and analyze the clinical effect and adverse reactions of recombinant human interleukin-2 immunization for injection in adjuvant therapy for pulmonary tuberculosis. Methods 64 patients with pulmonary tuberculosis were divided into treatment group (n=32) and control group (n=32).The control group received anti-tuberculosis chemotherapy regimen treatment,while the treatment group received recombinant human interleukin-2 for injection on this basis,once every other day and continuously for 2 months.By examining the sputum smear microscopic examination and chest X-ray examination results before and after treatment in the two groups,the clinical treatment effects and adverse reactions of the two groups were compared and analyzed. Results The sputum negative conversion rate of the treatment group was significantly higher than that of the control group (29/22 cases),and the difference was statistically significant (P<0.05).The significant absorption rate of lesions (19/11 cases) and the closure rate of cavities (15/7 cases) in the treatment group were better than those in the control group,with statistically significant differences (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Recombinant human interleukin-2 (recombinant human interleukin-2 for injection) is safe, effective and worthy of clinical application.